A1,
A2,
B,
C1,
C2,
D,
E,
F,
G-H,
I-K,
L,
M,
N,
O,
P1,
P2,
Q-R,
S,
T,
U-V,
W-Z
Daranide Warnings, Precautions, Pregnancy, Nursing, Abuse - Dichlorphenamide
Daranide Warnings, Precautions, Pregnancy, Nursing, Abuse - Dichlorphenamide
WARNINGS
No information provided.
PRECAUTIONS
General
Potassium excretion
is increased by DARANIDE and hypokalemia
may develop with brisk diuresis,
when severe cirrhosis
is present, or during concomitant use of steroids or ACTH.
Interference with adequate oral
electrolyte intake
will also contribute to
hypokalemia. Hypokalemia can sensitize or exaggerate the response
of the heart to the toxic
effects of digitalis
(e.g., increased ventricular irritability). Hypokalemia may be avoided
or treated by use of potassium supplements such
as foods with a high potassium
content. DARANIDE should be used with caution in patients with respiratory
acidosis.
Drug Interactions
Caution is advised in patients receiving concomitant
high-dose aspirin and carbonic
anhydrase inhibitors,
as anorexia, tachypnea,
lethargy and coma have
been rarely reported due to a possible drug
interaction.
Carcinogenesis, Mutagenesis, Impairment of Fertility
Long-term studies in animals have not been performed to evaluate
the effects upon fertility
or carcinogenic
potential of DARANIDE.
Pregnancy
Pregnancy Category C. Dichlorphenamide has been shown
to be teratogenic
in the rat (skeletal anomalies)
when given in doses 100 times the human
dose. There are no adequate
and well-controlled studies in pregnant
women. DARANIDE should not be used in women of childbearing age
or in pregnancy, especially
during the first trimester, unless the potential benefits outweigh
the potential risks.
Nursing Mothers
It is not known whether dichlorphenamide
is excreted in human milk.
Because many drugs are excreted in human
milk, caution should be exercised when dichlorphenamide
is administered to a nursing
woman.
Pediatric Use
Safety and effectiveness
in children have not been established.
top
